 Xiayuan Liang
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2020 | 293 | 1.150 |
Why?
| | Receptor Protein-Tyrosine Kinases | 8 | 2013 | 230 | 0.750 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 12 | 0.640 |
Why?
| | Gene Rearrangement | 3 | 2013 | 155 | 0.610 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 4 | 2016 | 192 | 0.590 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 132 | 0.580 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 2 | 2013 | 22 | 0.580 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2018 | 10 | 0.570 |
Why?
| | Biomarkers, Tumor | 4 | 2018 | 1313 | 0.570 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2018 | 20 | 0.570 |
Why?
| | Leukemoid Reaction | 1 | 2016 | 3 | 0.510 |
Why?
| | GATA1 Transcription Factor | 1 | 2016 | 18 | 0.500 |
Why?
| | Genetic Association Studies | 1 | 2018 | 372 | 0.490 |
Why?
| | Diseases in Twins | 1 | 2016 | 115 | 0.480 |
Why?
| | Point Mutation | 1 | 2016 | 243 | 0.470 |
Why?
| | Hyaluronan Receptors | 2 | 2002 | 102 | 0.350 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 167 | 0.350 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 57 | 0.320 |
Why?
| | Glycoproteins | 2 | 2002 | 355 | 0.310 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2363 | 0.310 |
Why?
| | Down Syndrome | 1 | 2016 | 534 | 0.300 |
Why?
| | Proto-Oncogene Proteins | 5 | 2013 | 623 | 0.290 |
Why?
| | Killer Cells, Natural | 2 | 2008 | 467 | 0.250 |
Why?
| | Flow Cytometry | 5 | 2018 | 1173 | 0.250 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2013 | 322 | 0.250 |
Why?
| | Leukemia | 1 | 2008 | 245 | 0.230 |
Why?
| | Chromosome Aberrations | 3 | 2018 | 162 | 0.230 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 101 | 0.230 |
Why?
| | Immunohistochemistry | 5 | 2013 | 1716 | 0.230 |
Why?
| | Hodgkin Disease | 1 | 2007 | 171 | 0.220 |
Why?
| | Skin Neoplasms | 2 | 2002 | 847 | 0.220 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 2004 | 12 | 0.210 |
Why?
| | Proto-Oncogenes | 1 | 2004 | 29 | 0.210 |
Why?
| | Cytogenetic Analysis | 2 | 2020 | 33 | 0.210 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2003 | 19 | 0.200 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 433 | 0.200 |
Why?
| | Eye Neoplasms | 1 | 2003 | 30 | 0.200 |
Why?
| | Stem Cells | 1 | 2008 | 626 | 0.200 |
Why?
| | Child | 14 | 2020 | 22633 | 0.200 |
Why?
| | Lymphomatoid Papulosis | 1 | 2002 | 1 | 0.190 |
Why?
| | Anaplasia | 1 | 2002 | 7 | 0.180 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.170 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 41 | 0.170 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 91 | 0.160 |
Why?
| | Child, Preschool | 9 | 2019 | 11787 | 0.160 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 89 | 0.160 |
Why?
| | Liver Transplantation | 1 | 2007 | 823 | 0.150 |
Why?
| | Retrospective Studies | 7 | 2020 | 17066 | 0.150 |
Why?
| | Infant | 9 | 2019 | 10034 | 0.150 |
Why?
| | Castleman Disease | 1 | 2019 | 16 | 0.150 |
Why?
| | Translocation, Genetic | 2 | 2013 | 115 | 0.140 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2019 | 29 | 0.140 |
Why?
| | Male | 15 | 2021 | 72315 | 0.140 |
Why?
| | Karyotyping | 1 | 2018 | 106 | 0.140 |
Why?
| | Histocytochemistry | 1 | 2018 | 79 | 0.140 |
Why?
| | Immunophenotyping | 3 | 2004 | 322 | 0.140 |
Why?
| | Humans | 25 | 2021 | 144759 | 0.130 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 150 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1953 | 0.130 |
Why?
| | Pregnancy, Triplet | 1 | 2016 | 5 | 0.130 |
Why?
| | Female | 15 | 2021 | 78271 | 0.120 |
Why?
| | Organic Cation Transport Proteins | 1 | 2016 | 25 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 339 | 0.120 |
Why?
| | Twins, Monozygotic | 1 | 2016 | 134 | 0.120 |
Why?
| | Transcription Factors | 1 | 2004 | 1741 | 0.120 |
Why?
| | Prognosis | 4 | 2019 | 4282 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1075 | 0.110 |
Why?
| | RNA, Small Interfering | 3 | 2013 | 635 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2006 | 983 | 0.100 |
Why?
| | Trans-Activators | 1 | 2016 | 405 | 0.100 |
Why?
| | Databases, Factual | 1 | 2019 | 1486 | 0.100 |
Why?
| | c-Mer Tyrosine Kinase | 5 | 2013 | 38 | 0.090 |
Why?
| | Hypoproteinemia | 1 | 2012 | 5 | 0.090 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 19 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2021 | 6429 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2879 | 0.090 |
Why?
| | Adolescent | 6 | 2019 | 22428 | 0.090 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2013 | 210 | 0.090 |
Why?
| | Edema | 1 | 2012 | 124 | 0.080 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2012 | 62 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 432 | 0.080 |
Why?
| | Apoptosis | 2 | 2010 | 2430 | 0.080 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 6 | 0.080 |
Why?
| | Anterior Chamber | 1 | 2009 | 27 | 0.070 |
Why?
| | Astrocytoma | 1 | 2010 | 129 | 0.070 |
Why?
| | Shock, Hemorrhagic | 1 | 2011 | 201 | 0.070 |
Why?
| | DNA-Binding Proteins | 2 | 2008 | 1499 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2011 | 303 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4564 | 0.070 |
Why?
| | Eye Diseases | 1 | 2009 | 94 | 0.070 |
Why?
| | Blood Platelets | 1 | 2011 | 400 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2018 | 11679 | 0.070 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 3 | 0.060 |
Why?
| | Adenoids | 1 | 2007 | 12 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 294 | 0.060 |
Why?
| | Palatine Tonsil | 1 | 2007 | 55 | 0.060 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 17 | 0.060 |
Why?
| | Platelet Aggregation | 1 | 2006 | 105 | 0.060 |
Why?
| | Gene Knockdown Techniques | 3 | 2013 | 336 | 0.060 |
Why?
| | Adult | 7 | 2019 | 40449 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 380 | 0.060 |
Why?
| | Immunocompromised Host | 1 | 2007 | 201 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 247 | 0.060 |
Why?
| | Precancerous Conditions | 1 | 2007 | 166 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 158 | 0.060 |
Why?
| | Phagocytosis | 1 | 2006 | 299 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 881 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2007 | 502 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1054 | 0.050 |
Why?
| | Pregnancy | 1 | 2016 | 7190 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2004 | 72 | 0.050 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2003 | 20 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 200 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2011 | 956 | 0.050 |
Why?
| | RNA, Viral | 1 | 2007 | 688 | 0.050 |
Why?
| | Ki-1 Antigen | 1 | 2002 | 7 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2003 | 222 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1137 | 0.050 |
Why?
| | Mice, Transgenic | 2 | 2021 | 2182 | 0.050 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2004 | 141 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2013 | 56 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2010 | 1318 | 0.040 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2021 | 134 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 688 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 1266 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 320 | 0.040 |
Why?
| | Survival Rate | 2 | 2019 | 2089 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 304 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2021 | 379 | 0.040 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 68 | 0.040 |
Why?
| | Macrophages | 1 | 2006 | 1511 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1253 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2013 | 928 | 0.030 |
Why?
| | Autoantigens | 1 | 2021 | 429 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 919 | 0.030 |
Why?
| | Organic Cation Transporter 2 | 1 | 2016 | 8 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2115 | 0.030 |
Why?
| | Mice | 4 | 2021 | 18339 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2004 | 3409 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2021 | 876 | 0.030 |
Why?
| | Autoimmunity | 1 | 2021 | 926 | 0.030 |
Why?
| | Middle Aged | 3 | 2019 | 35875 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 376 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2847 | 0.030 |
Why?
| | Animals | 5 | 2021 | 38058 | 0.030 |
Why?
| | Autoantibodies | 1 | 2021 | 1501 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2021 | 2050 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3162 | 0.020 |
Why?
| | Risk Assessment | 1 | 2002 | 3671 | 0.020 |
Why?
| | Protein-Losing Enteropathies | 1 | 2012 | 10 | 0.020 |
Why?
| | Hypoalbuminemia | 1 | 2012 | 28 | 0.020 |
Why?
| | Aged | 2 | 2002 | 25913 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1985 | 0.020 |
Why?
| | Platelet Activation | 1 | 2011 | 104 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2194 | 0.020 |
Why?
| | Suppuration | 1 | 2009 | 9 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 194 | 0.020 |
Why?
| | Cytarabine | 1 | 2009 | 66 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5408 | 0.020 |
Why?
| | Injections, Spinal | 1 | 2009 | 120 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 105 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 11 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 369 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 610 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5226 | 0.020 |
Why?
| | Inflammation | 1 | 2019 | 2878 | 0.020 |
Why?
| | Metalloproteases | 1 | 2006 | 42 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2006 | 114 | 0.010 |
Why?
| | Solubility | 1 | 2006 | 242 | 0.010 |
Why?
| | Cell Survival | 1 | 2009 | 1098 | 0.010 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 86 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2527 | 0.010 |
Why?
| | Thromboembolism | 1 | 2006 | 125 | 0.010 |
Why?
| | Macrophage Activation | 1 | 2006 | 193 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3540 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 381 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 969 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5597 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2496 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5992 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 14105 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2006 | 1455 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1496 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2006 | 1982 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 5960 | 0.010 |
Why?
|
|
Liang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|